We are providing the following business update.
Recent Developments
On
November 17, 2021 the Company announced topline results from the monotherapy arms of its Phase 2 clinical trial of ELX-02 in Class
1 cystic fibrosis (CF) patients with at least one G542X nonsense allele mutation. ELX-02 was well tolerated and achieved a statistically
significant 5.4 mmol/L reduction in sweat chloride in patients at the 1.5 mg/kg/day dose. The intra-patient dose escalation stage of the
trial has successfully identified 1.5 mg/kg/day as the dose for further development. Based on the statistically significant monotherapy
results observed at the 1.5 mg/kg/day dose, planning for the advancement of ELX-02 into Phase 3 clinical development has started. The
Company conducted the study in the United States and Israel under substantially similar protocols and the data reported reflects the results
across both geographic regions.
The corporate update also included the following information:
/ 1 ELX - 02 Phase 2 design ClinicalTrials.gov Identifier: US Trial NCT04135495, EU/IL Trial NCT04126473 * From baseline to Day 7 of treatment periods 1 - 3, and Days 7 and 14 of treatment period 4 ELX - 02 Phase 2 CF trial designed to evaluate safety and sweat chloride reduction 0.3 mg/kg SC QD for 7 days Dose 1 0.75 mg/kg SC QD for 7 days Dose 2 1.5 mg/kg SC QD for 7 days Dose 3 Up to 3 mg/kg SC QD for 14 days Dose 4 Population • Up to 24 CF patients with a G542X mutation on one or both alleles Primary outcome measures • Safety, tolerability , and pharmacokinetics Key Secondary outcome measures • Change from baseline in sweat chloride concentration* • Change from baseline in percent predicted forced expiratory volume (ppFEV1)* Locations • Europe, Israel, USA, Canada and Australia
/ 2 No ELX - 02 related serious adverse events seen ELX - 02 safety summary Injection site reactions were the most common finding across the patients – Mild erythema or redness – Mild - moderate Injection pain Drug related discontinuations – Tinnitus (mild - moderate) 1 patient at 0.3 mg/kg • Occurred in patient with pre - existing tinnitus after exposure to loud music • Reported after first dose and resolved during follow - up • Case was reviewed by Audiology and SRC – did not have a safety concern – Injection site reaction in 3 patients • 1 at 0.75 mg/kg • 2 at the highest dose level of up to 3 mg/kg Ivacaftor combination amendment is approved in all participating countries with no significant safety concerns
/ 3 * CLSI. Sweat Testing: Third Edition. CLSI document C34 - A3. Wayne, PA: Clinical and Laboratory Standards Institute ; 2009 ** Am J Respir Crit Care Med Jun 3 2016 Sweat chloride secondary endpoint analysis performed using standard criteria Key statistical assessment to ensure appropriate baseline values Sweat chloride levels collected on both arms* • Values with difference >15 mmol/L excluded Average baseline calculated: • Sweat chloride collected on screening and prior to drug administration • Values with difference > 15 mmol/L between values excluded** • Baseline based on the average of the above two values Sweat chloride collected at the end of each treatment period Drug response evaluated based on difference between end of the treatment period to the average baseline for each patient
/ 4 Activity in Phase 2 of ELX - 02 treated Class 1 CF patients † p value did not reach significance * p value one - sided t - test =0.022 non - parametric =0.026 ** Results for patients receiving variable doses up to 3.0 mg/kg were not significant. Moreover, inconsistent dosing (as seen in pharmacokinetic results) and fewer completers among patients at these variable dose levels limited the interpretability of the related data and the ability to draw meaningful conclusions. B ase d on these findings, Eloxx does not plan to continue evaluation of doses above 1.5mg/kg and up to a 3.0 mg/kg. CF patients receiving 1.5mg/kg/day had statistically significant sweat chloride reduction of 5.4mmol/L after 1 week -14 -12 -10 -8 -6 -4 -2 0 2 4 6 8 - 5.4 ELX - 02 (0.75 mg/kg) ELX - 02 (0.3 mg/kg) ELX - 02 (1.5 mg/kg) - 0.2 † 1.3 † n=20 n =17 † n=12 Mean sweat chloride changes in Hom and Het G542X CF patients on 1 week treatment with ELX - 02 (mmol/L)* p value=0.022* Plan to advance to Phase 3 • Biologic signal detected at 1.5 mg/kg/day dose** despite short duration and small sample size. Suggests likely improvement in FEV1 after longer treatment duration • Trend towards dose response
/ 5 Post - hoc subset analysis of sweat chloride change in 1.5mg/kg/day completers Stronger evidence of dose response in subset analysis of 1.5mg/kg dose completers -14 -12 -10 -8 -6 -4 -2 0 2 4 6 8 0.8 † - 2.6 † ELX - 02 (0.3 mg/kg) ELX - 02 (0.75 mg/kg) - 5.4 ELX - 02 (1.5 mg/kg) Sweat chloride changes (mmol/L) in Hom and Het G542X CF patients on 1 week treatment with ELX - 02 at 1.5mg/kg dose (n=12) p value = 0.022* † p value did not reach significance * p value one - sided t - test =0.022 non - parametric =0.026
Forward-looking Statements
This current report contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of present and historical
facts contained in this current report, including without limitation, statements regarding the expected timing of trials and results from
clinical studies of our product candidates and the potential of our product candidate to treat nonsense mutations are forward-looking
statements. Forward-looking statements can be identified by the words “aim,” “may,” “will,” “would,”
“should,” “expect,” “explore,” “plan,” “anticipate,” “could,”
“intend,” “target,” “project,” “contemplate,” “believe,” “estimate,”
“predict,” “potential,” “seeks,” or “continue” or the negative of these terms similar
expressions, although not all forward-looking statements contain these words.
Forward-looking statements are based on management's
current plans, estimates, assumptions and projections based on information currently available to us. Forward-looking statements are subject
to known and unknown risks, uncertainties and assumptions, and actual results or outcomes may differ materially from those expressed or
implied in the forward-looking statements due to various important factors, including, but not limited to: our ability to progress any
product candidates in preclinical or clinical trials; the uncertainty of clinical trial results and the fact that positive results from
preclinical studies are not always indicative of positive clinical results; the scope, rate and progress of our preclinical studies and
clinical trials and other research and development activities; the competition for patient enrollment from drug candidates in development;
the impact of the global COVID-19 pandemic on our clinical trials, operations, vendors, suppliers, and employees; our ability to obtain
the capital necessary to fund our operations; the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual
property rights; our ability to obtain financial in the future through product licensing, public or private equity or debt financing or
otherwise; general business conditions, regulatory environment, competition and market for our products; and business ability and judgment
of personnel, and the availability of qualified personnel and other important factors discussed under the caption “Risk Factors”
in our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021, as any such factors may be updated from time to
time in our other filings with the SEC, accessible on the SEC’s website at www.sec.gov and the “Financials & Filings”
page of our website at https://investors.eloxxpharma.com/financial-information/sec-filings.
All forward-looking statements speak only as of
the date of this Current Report on Form 8-K and, except as required by applicable law, we have no obligation to update or revise any forward-looking
statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.